*FreeStyle Libre 2 system: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
†FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
‡The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView.
IIData from this study was collected with the outside US version of Freestyle Libre 14 day system. Freestyle Libre 2 has the same features as Freestyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
¶Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
#Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
**Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
†† or ♢Eligible patients will receive one (1) FreeStyle Libre 14 day sensor or one (1) FreeStyle Libre 2 sensor and reader at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is not available for patients with gestational diabetes. Only patients 18 and older are eligible to receive an offer for the FreeStyle Libre 14 day sensor, and patients 4 and older are eligible to receive an offer for the FreeStyle Libre 2 sensor and reader. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs or residents of Massachusetts, Puerto Rico and other US territories. The free FreeStyle Libre 14 day sensor or FreeStyle Libre 2 sensor and reader is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 14 day sensor or FreeStyle Libre 2 sensor and reader cannot be re-sold, traded nor submitted to any third party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
References: 1. Cengiz, Eda, and William V Tamborlane. “A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring.” Diabetes Technology & Therapeutics 11, Suppl 1 (June 2009): S11-6. doi:10.1089/dia.2009.0002. 2. Bolinder, Jan, et al. “Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial.” The Lancet 10057, no. 388 (September 2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 3. Haak, Thomas, et al. “Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial.” Diabetes Therapy 8, no. 1 (February 2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 4. Evans, Mark, et al. “The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies.” Diabetes Therapy 11, no. 1 (January 2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 5. Kroeger, Jens, Peter Fasching, and Helene Hanaire. “Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes.” Diabetes Therapy 11, no. 1 (January 2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 6. Data on file. Abbott Diabetes Care.
ADC-36557 Ver 1.0 04/21